News

As part of the deal, Roche will make an upfront cash payment of $250m to Santaris shareholders and make additional contingent payments of up to $200m based on

By joining The US Oncology Network, the physicians at Optim Oncology and Urology Centers of Oklahoma can collaborate with other oncology experts from across the nation in real

RXDX-103 is an inhibitor of the cell division cycle 7-related (Cdc7) protein kinase, and RXDX-104 is a program to identify a highly selective inhibitor of the rearranged during

In exchange for a one-time, upfront payment of $5.0 million, Infinity receives an option to terminate its obligation to pay Millennium future royalties related to the sale of

The acquisition will include the Intellectual Properties ("IP"), assets and talents of this cancer-therapy-focused developmental stage company. The IP is comprised of T Cells Receptor ("TCR") clonality analysis

The deal provides toxicity and efficacy studies of cannabinoid formulations carried out in animal models for neurobehavioral diseases including sleep disorders. The company said that the first formulation

In the trial, dosing of the first infant will be carried out within the next few weeks, when Isis will receive an $18m milestone payment from its development

Striverdi Respimat, a long-acting beta agonist (LABA) delivered via a propellant-free inhaler, is not indicated for the treatment of acute deteriorations of COPD and also for asthma. The

Additionally, ANI acquired approved ANDAs from Shire for the currently non-marketed products vancomycin hydrochloride injectable 500mg, 1gm and 10gm and vancomycin hydrochloride oral solution 250mg and 500mg. In